Aptevo Therapeutics (APVO) Income from Discontinued Operations (2016 - 2020)
Aptevo Therapeutics (APVO) posted Income from Discontinued Operations of 1580000.0 for Q1 2020, up 58.16% sequentially from 999000.0 in Q3 2019, and up 470.4% YoY from 277000.0 in Q2 2019.
Aptevo Therapeutics (APVO) Income from Discontinued Operations (2016 - 2020) Analysis & Trends
Aptevo Therapeutics has reported Income from Discontinued Operations for 4 years, with the latest figure at 1580000.0 in Q1 2020.
- Quarterly Income from Discontinued Operations rose 470.4% year-over-year to 1580000.0 in Q1 2020, while the trailing twelve-month figure through Jun 2020 was 5071000.0 (down 79.09% YoY) and the FY2017 annual result came in at 23299000.0, up 435.36% from the prior year.
- Income from Discontinued Operations grew to 1580000.0 in Q1 2020 per APVO's latest filing, from 999000.0 in the prior quarter.
- Over five years, Income from Discontinued Operations peaked at 21257000.0 in Q3 2017 and troughed at 223000.0 in Q4 2017.
- A 4-year average of 3204000.0 and a median of 1050500.0 in 2016 frame the typical range for Income from Discontinued Operations.
- The widest YoY moves for Income from Discontinued Operations: up 827.85% in 2017, down 79.76% in 2017.
- Over 4 years, Income from Discontinued Operations stood at 1102000.0 in 2016, then slumped by 79.76% to 223000.0 in 2017, then soared by 347.98% to 999000.0 in 2019, then surged by 58.16% to 1580000.0 in 2020.
- According to Business Quant data, Income from Discontinued Operations over the past three periods registered 1580000.0, 999000.0, and 2492000.0 for Q1 2020, Q3 2019, and Q2 2019 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Aptevo Therapeutics | 3.18 Mn | -6.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 1.58 Mn |
| Sep 30, 2019 | 999,000.00 |
| Jun 30, 2019 | 2.49 Mn |
| Mar 31, 2019 | 277,000.00 |
| Dec 31, 2017 | 223,000.00 |
| Sep 30, 2017 | 21.26 Mn |
| Jun 30, 2017 | 996,000.00 |
| Mar 31, 2017 | 823,000.00 |
| Dec 31, 2016 | 1.10 Mn |
| Sep 30, 2016 | 2.29 Mn |